The clinical pattern of HER - 2/neu oncogene overexpressing breast cancer in Pakistani patients at initial presentation: An Analysis of HER - 2/neu positive versus negative disease - A preliminary report

Journal of the Pakistan Medical Association

Volumn 49, Issue 12, 1999, Pages 294-297

  Siddiqui, Tariq ^a   Khan, Shaista ^a   Kayani, Naila ^a   Salam, Abdul ^a   Kiran, Saima ^a   Jilani, Syed Moinuddin ^a  

^a AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAKISTAN; PROGNOSIS; PROTO ONCOGENE;

ADULT; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PAKISTAN; PROGNOSIS;

EID: 0033253336     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. De Potter CR. The new oncogene more than a prognostic indicator. Human Pathology, 1994;25:1264-68.
2. Lupu R, Cardillo M, Harris L, et al. Interaction between ERB receptors and heregulin in breast cancer tumor progression and drug resistance. Semin Cancer Biol., 1995;6:135-45.
3. Dickson RB, Lippman ME. Biologic factors in breast cancer. In Diseases of the Breast (eds) Ed. Harris JR, Lippman ME, Morrow M, et al., Chapter 7, Philodelphia, New York, Lippencott Raven, p.221.
4. Seshadari R, Firgario FA, Horsfall DJ, et al. Clincal significance of HER-2/neu oncogene amplification in primary breast cancer 3. Clin, oncol., 1993;11:1936-42.
5. Bishop JM. Viral Oncogenes. Cell, 1985;42:23-38.
6. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node negative patients. Prognostic significance of overexpression influenced by the presence of insitu carcinoma. J. Clin. Oncol., 1992;10:599-605.
7. Muss HB, Thor AD, Berry DA, et al. C-erb B-2 expression and benefit from adjunctive chemotherapy and radiotherapy of Breast cancer. N. Engl., J. Med., 1994;330:1260-66.
8. Carlomagno C, Perrone F, Gallo C, et al. Cerbe-B2 overexpression decreases the benefit of adjuvant tamoxifen in early stage breast cancer without axillary node metastasis. J. Clin. Oncol., 1996;14:2702-8.
9. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of Herceptin as a single agent in 222 women with HER-2/neu overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc. Am. Soc. Clin. Oncl., 1998. 17.97a.
10. c-erb B-2 Oncoprotein. Instructions for use. Glostrup. Denmark, 1998.
11. O'Reilly SM, Barnes DM, Campeljohn RS, et al. The relationship between C-erb B2 expression S Phase fraction and prognosis in Breast cancer Br. J. Cancer. 1991;63:444-46.